Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 11/20 | 0.61 |
| ▸ | JAK2 | O60674 | 3/20 | 0.47 |
| ▸ | JAK1 | P23458 | 3/20 | 0.47 |
| ▸ | JAK3 | P52333 | 3/20 | 0.47 |
| ▸ | TYK2 | P29597 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TOP1 | P11387 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29360706 | 0.93 | TDP1 (0.69) | TDP1JAK2JAK1JAK3TYK2 | |
| SCHEMBL241242 | 0.93 | TDP1 (0.69) | TDP1JAK2JAK1JAK3TYK2 | |
| SCHEMBL3728817 | 0.92 | TDP1 (0.60) | TDP1JAK2JAK1JAK3TYK2 | |
| SCHEMBL3720038 | 0.91 | TDP1 (0.59) | TDP1JAK2JAK1JAK3TYK2 | |
| SCHEMBL12457207 | 0.91 | TDP1 (0.52) | TDP1JAK2JAK1JAK3TYK2 | |
| SCHEMBL3722720 | 0.90 | TDP1 (0.58) | TDP1JAK2JAK1JAK3TYK2 | |
| SCHEMBL3721281 | 0.90 | TDP1 (0.57) | TDP1JAK2JAK1JAK3TYK2 | |
| SCHEMBL3721285 | 0.90 | TDP1 (0.57) | TDP1JAK2JAK1JAK3TYK2 | |
| SCHEMBL3722560 | 0.89 | TDP1 (0.58) | TDP1JAK2JAK1JAK3TYK2 | |
| SCHEMBL19456978 | 0.89 | TDP1 (0.59) | TDP1JAK2JAK1JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321781-B2 | Topoisomerase inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-04-26 | — | — | US | claimed |
| US-20120237531-A1 | TOPOISOMERASE INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-09-20 | — | — | US | claimed |
| WO-2010127363-A1 | TOPOSIOMERASE INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-11-04 | — | — | WO | claimed |
| WO-2010127360-A1 | TOPOSIOMERASE INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-11-04 | — | — | WO | claimed |
| US-9321781-B2 | Topoisomerase inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321781-B2 | Topoisomerase inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-04-26 | — | — | US | disclosed |
| US-20120237531-A1 | TOPOISOMERASE INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-09-20 | — | — | US | disclosed |
| US-20120237531-A1 | TOPOISOMERASE INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-09-20 | — | — | US | disclosed |
| WO-2010127360-A1 | TOPOSIOMERASE INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127363-A1 | TOPOSIOMERASE INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127363-A1 | TOPOSIOMERASE INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127360-A1 | TOPOSIOMERASE INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120237531-A1 | TOPOISOMERASE INHIBITORS | TOP1, TOP2A, TOP2B | TDP1 10/4885JAK2 1816/4885JAK1 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.